Andrew Conrad, PhD, is the Co-Founder and Executive Chairman of Verily. Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LabCorp). Dr. Conrad co-founded the National Genetics Institute, where he served as Chief Scientific Officer. He is a Working Group Member on the Precision Medicine Initiative and a member of the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Scientific Advisory Board.

Stephen Gillett is the Chief Executive Officer at Verily, where he leads multi-disciplinary health, technology and business teams to advance the company's precision health purpose. Before his appointment as CEO, Stephen was Verily’s President & COO overseeing engineering, business and commercial operations. Prior to joining Verily, Stephen was co-founder and CEO of Chronicle, an Alphabet cybersecurity company that is now part of Google Cloud. He is an active advisor to GV and X. Prior to Alphabet, Stephen served as EVP, COO and board member at Symantec, a Fortune 500 Enterprise Technology Company. He also served as the EVP and President of Best Buy Digital and Business Operations, and was part of the founding Starbucks transformation leadership team as Chief Information Officer and General Manager of Digital Ventures. Stephen sits on the Board of Directors for Discord, Dutch Bros and the University of Oregon, Phil and Penny Knight Campus for Accelerating Scientific Impact. He was recognized by Amazon in 2019 as a best selling author for his book “From Simi Valley To Silicon Valley.” He holds an MBA from San Francisco State University and a BS from the University of Oregon.

Amy Abernethy is the President of Product Development and Chief Medical Officer at Verily, where she leads teams in the development and delivery of products that bridge the gap between clinical research and care. Dr. Abernethy was most recently Principal Deputy Commissioner of Food and Drugs of the US Food and Drug Administration (FDA) and the agency's acting Chief Information Officer. Prior to her role at the FDA, Dr. Abernethy was Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Oncology of Flatiron Health. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. Dr. Abernethy is a hematologist/oncologist and palliative medicine physician who has authored more than 500 publications. She holds a BA in Biochemistry from the University of Pennsylvania, an MD from Duke University School of Medicine, and a PhD in Evidence Based Medicine and Informatics from Flinders University in Australia.

Scott Burke is the Chief Technology Officer at Verily, where he leads the company’s software and hardware engineering, AI and data science, and UX teams in the development of innovative products and platforms that power precision health. Prior to Verily, Scott was Co-founder and Chief Technology Officer for Helix, a leading population genomics company. Before Helix, Scott worked for nine years at Yahoo, most recently as Senior Vice President of Advertising and Data Platforms. Scott also previously led engineering teams at two mobile startups, Seven Networks and PacketHop, and was Vice President of Engineering for WebMD. Scott started his career as a computational physicist at Hewlett-Packard. He holds a bachelor’s degree in physics from Harvey Mudd College in Claremont, California.

Lisa Greenbaum is the Chief Commercial Officer at Verily, where she leads sales, marketing, and customer success teams with a focus on maximizing value for customers and driving a deep understanding of their needs across the organization. Prior to Verily, Lisa was Chief Client Officer at Progyny where she led sales, account management, and channel partnerships. She joined Progyny prior to the IPO and was a key contributor to the company’s growth during her tenure. Before Progyny, Lisa spent 15 years at WebMD where she was Group General Manager of Medscape Professional Services and led sales, account management, product marketing and revenue delivery. Lisa has also held senior sales roles in the pharmaceutical and digital health space at HealthStream, Merck, and Procter & Gamble. She holds a bachelor’s degree from Duke University.

Cynthia Patton, JD , is the Chief Legal Officer at Verily, where she leads legal, privacy, compliance and government affairs teams. Previously, she served as senior vice president and chief compliance officer at Amgen, where she was responsible for Amgen’s global privacy and compliance organization. She also served as chair of the Amgen Foundation. Prior to Amgen, she served as general counsel of SCAN Health Plan, a California Health Maintenance Organization (HMO). Cynthia received her JD from George Washington University and her bachelor’s degree from Vassar College, and is admitted to the State Bar of California, State Bar of Georgia and the District of Columbia Bar.

Kerrie Peraino is the Chief People Officer at Verily, where she oversees all People Operations activities, including talent and leadership development, talent acquisition, learning, compensation and benefits, diversity and inclusion and employee relations. Prior to Verily, Kerrie was VP, People Operations, at Google, where she led frontline HR and delivered world-class HR services to over 130,000 Google employees. Before Google, Kerrie spent more than 20 years at American Express in the U.S. and the U.K., where, among other HR roles of increasing responsibility, she served as Chief Diversity Officer, Chief Talent Officer, and Senior Vice President of Global Talent Management. She holds a BA in Communications from Rutgers University and an MA in Corporate Communications from Seton Hall University.

Preston Simons is the Chief Information Officer at Verily, where he is responsible for building out our IT strategies, systems and processes. Previously, Preston was President and Managing Partner of Simons & Associates, LLC, where he consulted companies on driving business value through transformation of organizational practices, business processes, and technology alignment and implementation. He also specialized in merger and acquisition planning and coordination, IT transformation, integration, and technology strategy engagement. Preston has served in C-level positions for several decades across companies such as Aurora Healthcare, Abbott Laboratories (a Fortune 100 life sciences and medical device company), and Smithkline Beecham (GSK). He is a member of the Board of Governors for the Opus College of Business at the University of St. Thomas, Minnesota, and is an Advisory Board member for Infinity Systems, Inc. He is a certified Board Leadership Fellow of the National Association of Corporate Directors. Preston earned his MBA from the Booth School of Business at the University of Chicago and a BS degree in Management and Computer Science from the Illinois Institute of Technology.

Denny is a veteran executive, having spent 35 years in healthcare financing and operations. Prior to serving as CEO of Granular, his background included a four-year tenure as CEO of Hixme, a digital health benefits platform for large employers, and a 20-year tenure with Wellpoint (Anthem), serving as CEO for a number of its nationwide insurance companies. In his earlier career, Denny served Deloitte Consulting for six years as a consultant in the insurance, benefits and healthcare industries, and he spent six years as chief engineer and general manager of the CTX division of IC Industries. Denny’s private equity board involvements have included Renal Ventures Management, Applied Merchant Systems, Westlake Davvar and Skyview Development. He has also held startup advisory and/or board positions with Outpatient, Focal Scan Systems, and Hixme. Denny’s public company board involvements have included Dole Food Company, Salem Communications Corp, Health Management, Inc. and Wellpoint/Anthem.

Dennis A. Ausiello, MD, is the Jackson Distinguished Professor of Clinical Medicine and director emeritus of the MD/PhD Program at Harvard Medical School. He is also chairman of Medicine emeritus and director of the Center for Assessment Technology and Continuous Health (CATCH) at the Massachusetts General Hospital (MGH). This center is a partnership among MGH, MIT, and Harvard University whose mission is to develop real-time assessment of human traits in wellness and disease. A graduate of Harvard and the University of Pennsylvania, Dennis is a nationally recognized leader in academic medicine who understands the needs for partnerships between the academy and industry.

Linda Avey is co-founder & CEO of Precise.ly, a precision medicine engine providing deep genetic insights to patients with chronic conditions. The company's goal is to identify disease subtypes leading to more precise diagnoses and treatments. In 2006, Avey co-founded 23andMe, the leading direct-to-consumer genetics company. The idea for 23andMe came during her tenure at Affymetrix and Perlegen Sciences, where she observed gaps in the US research model that could be solved through a web- and consumer-based approach. 23andMe now houses the world's largest genetic database with 80% of its participants powering the research mission. Prior to 23andMe, Linda had over 25 years' experience working with the biopharmaceutical and academic research industry.

Dimitri Azar, MD, MBA, is the Chief Executive Officer for Twenty/Twenty Therapeutics and former Dean of the University of Illinois College of Medicine. Dimitri is an ophthalmic surgeon who has made significant contributions to the treatment of corneal diseases and to advances in refractive surgery. He has served as a key adviser on Verily ophthalmic projects since 2014. Dimitri completed his residency and fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. He was Professor of Ophthalmology at Harvard Medical School before joining the University of Illinois as Head of the Ophthalmology Department. Dimitri received his MD from American University of Beirut and his MBA from University of Chicago, Booth School of Business.

Kathy Giusti, a multiple myeloma patient, is the founder and chief mission officer of the Multiple Myeloma Research Foundation (MMRF) and serves on its board of directors. Kathy has led the MMRF in establishing collaborative research models in the areas of tissue banking, genomics, and clinical trials that are dramatically accelerating the pace at which life saving treatments are brought to patients. She also leads the Kraft Precision Medicine Accelerator, a $20M endowed program at Harvard Business School (HBS) that is developing business models to speed breakthroughs in precision medicine for all cancers. She received her MBA from HBS and holds an honorary Doctorate from the University of Vermont.

Dr. Krishnan is the Chief Executive Officer of Rush University System for Health, an internationally known academic health center and health system in Chicago, Illinois. Dr. Krishnan has authored more than 50 textbook chapters and 450 peer-reviewed papers on the subjects of elderly depression, dementia, Alzheimer's, panic disorder, bipolar disorder in late life and obsessive-compulsive disorder.

Linda is the past SEVP and Chief Operating Officer at Manulife Financial (operating as John Hancock in the US) responsible for globally leading Technology, Advanced Analytics, Marketing, Innovation, Corporate Strategy and Corporate Development, Human Resources, Regulatory and Public Affairs, Global Resourcing and Procurement, and the Transformation Program. Prior to Manulife, Linda was the Executive Vice President of Digital, Payments and Cards at Royal Bank of Canada (RBC), responsible for Mobile and Online Banking, credit cards, co-brands, RBC Rewards, Merchant Solutions (Chair of Moneris Board of Directors), and Innovation for the retail bank. At RBC, she held a number of increasingly senior positions since joining in 2003.

Fabrizio Michelassi, MD, FACS, ESA (Hon.), SIC (Hon.), SACPNE (Hon.), is the Lewis Atterbury Stimson Professor of Surgery and Chairman of Surgery at Weill Cornell Medicine and Surgeon-in-Chief at New York Presbyterian/Weill Cornell Medical Center. A world-renowned gastrointestinal surgeon with a strong expertise in the surgical treatment of gastrointestinal and pancreatic cancers as well as inflammatory bowel disease, Dr. Michelassi has contributed new insight in the surgical treatment of pancreatic and colorectal cancers, ulcerative colitis and Crohn’s disease through research and participation in multiple clinical trials. A prolific author of more than 330 papers, book chapters and abstracts, he has edited a book on “Operative strategies in inflammatory bowel disease” and has produced fifteen instructional movies for surgeons on the surgical treatment of complications of Crohn’s disease and ulcerative colitis.

Stephen N. Oesterle, MD, is a venture partner at Cathay Capital and also serves as an advisor to EQT Partners and Temasek Holdings. He is currently a board director at Baxter International, Sigilon Therapeutics and Peijia Medical. He was formerly SVP for Medicine and Technology at Medtronic, and a member of its Executive Operating Committee for 14 years. He oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of Medtronic's Business Development and Strategy Committee that approved all corporate acquisitions. Steve graduated summa cum laude from Harvard and received his MD from Yale; he completed his residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.

Andy Slavitt was President Biden's White House Senior Advisor for the Covid response. He has led many of the nation's most important health care initiatives, serving as President Obama's head of Medicare and Medicaid and overseeing the turnaround, implementation and defense of the Affordable Care Act. Slavitt is the "outsider's insider", serving in leading private and non-profit roles in addition to his government services. he is founder and Board Chair Emeritus of United States of Care, a national non-profit health advocacy organization as well as a founding partner of Town Hall Ventures, a healthcare firm that invests in underrepresented communities. He co-chaired a national initiative on the future of health care at the Bipartisan Policy Center. He chronicles what goes on inside the government and across the nation at town halls, in USA Today, on his award-winning podcast In the Bubble, and on Twitter. He is the author of Preventable, a best-selling account of the US’s Coronavirus response released in 2021. A graduate of the University of Pennsylvania and Harvard Business School, he and his wife have two grown sons.